Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents
- 15 November 2010
- journal article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 4 (2), 115-127
- https://doi.org/10.1177/1756283x10387203
Abstract
Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract of unknown etiology. The diagnosis of IBS is made clinically, using symptom-based criteria such as the Manning or Rome criteria. Medical therapy for this condition has traditionally been directed towards symptom relief, using fiber or antispasmodic agents. In recent years, emerging data have confirmed the efficacy of antidepressants, psychological therapies, 5-HT3 antagonists, 5-HT4 agonists, and probiotics in the short-term treatment of IBS, although whether these therapies influence the long-term course of the disease is unknown. Increasing knowledge regarding the pathophysiological mechanisms underlying IBS has resulted in a number of novel molecular treatments, which show promise. These include therapies targeting gastrointestinal mucosal chloride channels and guanylate cyclase-C receptors, as well as highly selective agents influencing serotonergic transmission that, at the time of writing, do not appear to have any severe deleterious effects. In this article we provide a summary of current and emerging therapies in this field.Keywords
This publication has 109 references indexed in Scilit:
- Citalopram Provides Little or No Benefit in Nondepressed Patients With Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2010
- Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?American Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic reviewGut, 2008
- Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysisGut, 2008
- A synthetic prostone activates apical chloride channels in A6 epithelial cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Guidelines on the irritable bowel syndrome: mechanisms and practical managementGut, 2007
- Efficacy of On-Demand Asimadoline, a Peripheral κ-Opioid Agonist, in Females With Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2007
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updatedBritish Journal of Pharmacology, 2007
- Effect of a second-generation 2 ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndromeGut, 2007
- Irritable bowel syndrome in twins: genes and environmentGut, 2006